Trials / Terminated
TerminatedNCT00065728
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients With Subfoveal Exudative Age-Related Macular Degeneration (AMD)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL | One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2003-08-01
- Last updated
- 2013-09-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00065728. Inclusion in this directory is not an endorsement.